1
|
Wang CG, Li Z, Liu S, Ng CT, Marzuki M, Jeslyn Wong PS, Tan B, Lee A, Hui Lim CF, Bifani P, Fang Z, Ching Wong JC, Setoh YX, Yang YY, Mun CH, Fiona Phua SZ, Lim WQ, Lin L, Cook AR, Tanoto H, Ng LC, Singhal A, Leong YW, Loh XJ. N95 respirator decontamination: a study in reusability. Mater Today Adv 2021; 11:100148. [PMID: 34179746 PMCID: PMC8220445 DOI: 10.1016/j.mtadv.2021.100148] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 04/20/2021] [Accepted: 04/21/2021] [Indexed: 05/23/2023]
Abstract
The coronavirus disease 2019 (COVID-19) pandemic had caused a severe depletion of the worldwide supply of N95 respirators. The development of methods to effectively decontaminate N95 respirators while maintaining their integrity is crucial for respirator regeneration and reuse. In this study, we systematically evaluated five respirator decontamination methods using vaporized hydrogen peroxide (VHP) or ultraviolet (254 nm wavelength, UVC) radiation. Through testing the bioburden, filtration, fluid resistance, and fit (shape) of the decontaminated respirators, we found that the decontamination methods using BioQuell VHP, custom VHP container, Steris VHP, and Sterrad VHP effectively inactivated Cardiovirus (3-log10 reduction) and bacteria (6-log10 reduction) without compromising the respirator integrity after 2-15 cycles. Hope UVC system was capable of inactivating Cardiovirus (3-log10 reduction) but exhibited relatively poorer bactericidal activity. These methods are capable of decontaminating 10-1000 respirators per batch with varied decontamination times (10-200 min). Our findings show that N95 respirators treated by the previously mentioned decontamination methods are safe and effective for reuse by industry, laboratories, and hospitals.
Collapse
Affiliation(s)
- C-G Wang
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| | - Z Li
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| | - S Liu
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| | - C T Ng
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
| | - M Marzuki
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - P S Jeslyn Wong
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
| | - B Tan
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - A Lee
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - C F Hui Lim
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - P Bifani
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - Z Fang
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
| | - J C Ching Wong
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
| | - Y X Setoh
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
| | - Y Y Yang
- Institute of Bioengineering and Bioimaging, Agency for Science, Technology and Research (A∗STAR), 31 Biopolis Way, Nanos, 138669, Singapore
| | - C H Mun
- DSO National Laboratories, 12 Science Park Dr, 118225, Singapore
| | - S Z Fiona Phua
- DSO National Laboratories, 12 Science Park Dr, 118225, Singapore
| | - W Q Lim
- DSO National Laboratories, 12 Science Park Dr, 118225, Singapore
| | - L Lin
- ST Engineering Aerospace Engines Pte Ltd, 501 Airport Rd, 539931, Singapore
| | - A R Cook
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, 12 Science Drive 2, 117549, Singapore
| | - H Tanoto
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| | - L-C Ng
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
- School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, 637551, Singapore
| | - A Singhal
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - Y W Leong
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| | - X J Loh
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| |
Collapse
|
2
|
Dembele L, Ang X, Chavchich M, Bonamy GMC, Selva JJ, Lim MYX, Bodenreider C, Yeung BKS, Nosten F, Russell BM, Edstein MD, Straimer J, Fidock DA, Diagana TT, Bifani P. The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Sci Rep 2017; 7:2325. [PMID: 28539634 PMCID: PMC5443816 DOI: 10.1038/s41598-017-02440-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Accepted: 04/11/2017] [Indexed: 11/23/2022] Open
Abstract
Malaria control and elimination are threatened by the emergence and spread of resistance to artemisinin-based combination therapies (ACTs). Experimental evidence suggests that when an artemisinin (ART)-sensitive (K13 wild-type) Plasmodium falciparum strain is exposed to ART derivatives such as dihydroartemisinin (DHA), a small population of the early ring-stage parasites can survive drug treatment by entering cell cycle arrest or dormancy. After drug removal, these parasites can resume growth. Dormancy has been hypothesized to be an adaptive physiological mechanism that has been linked to recrudescence of parasites after monotherapy with ART and, possibly contributes to ART resistance. Here, we evaluate the in vitro drug sensitivity profile of normally-developing P. falciparum ring stages and DHA-pretreated dormant rings (DP-rings) using a panel of antimalarial drugs, including the Plasmodium phosphatidylinositol-4-OH kinase (PI4K)-specific inhibitor KDU691. We report that while KDU691 shows no activity against rings, it is highly inhibitory against DP-rings; a drug effect opposite to that of ART. Moreover, we provide evidence that KDU691 also kills DP-rings of P. falciparum ART-resistant strains expressing mutant K13.
Collapse
Affiliation(s)
- L Dembele
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - X Ang
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - M Chavchich
- Department of Drug Evaluation, Australian Army Malaria Institute, Brisbane, QLD, 4051, Australia
| | - G M C Bonamy
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - J J Selva
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - M Yi-Xiu Lim
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - C Bodenreider
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - B K S Yeung
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - F Nosten
- Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - B M Russell
- Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand
| | - M D Edstein
- Department of Drug Evaluation, Australian Army Malaria Institute, Brisbane, QLD, 4051, Australia
| | - J Straimer
- Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY, 10032, USA
| | - D A Fidock
- Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY, 10032, USA.,Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, NY, 10032, USA
| | - T T Diagana
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - P Bifani
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore. .,Department of Microbiology and Immunology Program, Yong Loo Lin School of Medicine, Life Sciences Institute, National University of Singapore, 119077, Singapore, Singapore.
| |
Collapse
|
3
|
Rao SPS, Lakshminarayana SB, Kondreddi RR, Herve M, Camacho LR, Bifani P, Kalapala SK, Jiricek J, Ma NL, Tan BH, Ng SH, Nanjundappa M, Ravindran S, Seah PG, Thayalan P, Lim SH, Lee BH, Goh A, Barnes WS, Chen Z, Gagaring K, Chatterjee AK, Pethe K, Kuhen K, Walker J, Feng G, Babu S, Zhang L, Blasco F, Beer D, Weaver M, Dartois V, Glynne R, Dick T, Smith PW, Diagana TT, Manjunatha UH. Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis. Sci Transl Med 2013; 5:214ra168. [DOI: 10.1126/scitranslmed.3007355] [Citation(s) in RCA: 111] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
4
|
Mäkinen J, Marjamäki M, Haanperä-Heikkinen M, Marttila H, Endourova LB, Presnova SE, Mathys V, Bifani P, Ruohonen R, Viljanen MK, Soini H. Extremely high prevalence of multidrug resistant tuberculosis in Murmansk, Russia: a population-based study. Eur J Clin Microbiol Infect Dis 2011; 30:1119-26. [PMID: 21394425 DOI: 10.1007/s10096-011-1200-7] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2010] [Accepted: 02/10/2011] [Indexed: 12/01/2022]
Abstract
Drug resistance and molecular epidemiology of tuberculosis (TB) in the Murmansk region was investigated in a 2-year, population-based surveillance of the civilian population. During 2003 and 2004, isolates from all culture-positive cases were collected (n = 1,226). Prevalence of multi-drug resistance (MDR) was extremely high, as 114 out of 439 new cases (26.0%), and 574 out of 787 previously treated cases (72.9%) were resistant to at least isoniazid (INH) and rifampin (RIF). Spoligotyping of the primary MDR-TB isolates revealed that most isolates grouped to the Beijing SIT1 genotype (n = 91, 79.8%). Isolates of this genotype were further analyzed by IS6110 RFLP. Sequencing of gene targets associated with INH and RIF resistance further showed that the MDR-TB strains are highly homogeneous as 78% of the MDR, SIT1 strains had the same resistance-conferring mutations. The genetic homogeneity of the MDR-TB strains indicates that they are actively transmitted in Murmansk.
Collapse
Affiliation(s)
- J Mäkinen
- Antimicrobial Resistance Unit, Mycobacterial Laboratory, National Institute for Health and Welfare, Kiinamyllynkatu 13, 20520 Turku, Finland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
A population-based molecular epidemiology investigation has been undertaken to evaluate tuberculosis transmission and control in the Brussels-Capital Region (Belgium). All tuberculosis cases reported from January 2003 to December 2004 were investigated. In total, 536 Mycobacterium tuberculosis isolates (89% of culture-positive samples) were genotyped by the newly standardised 24 loci-based mycobacterial interspersed repetitive unit-variable number tandem-repeat typing, spoligotyping and IS6110 fingerprinting. Of all the patients, 30% were grouped based on strain clusters, suggesting a transmission index of 20%. An unsuspected outbreak entailing > or = 23 patients was evidenced by molecular typing analysis and confirmed by contact tracing. Foreign-born status accounted for 79% of the studied patients, including 37.9% illegal immigrants and asylum seekers. Among foreign-born patients, asylum seekers and illegal immigrants were significantly less abundant in strain clusters than settled residents. Tuberculosis in the Brussels-Capital Region is a bi-faceted problem, comprising both persisting recent transmission and "imported diseases". Molecular epidemiology based on real-time genotyping techniques has proven invaluable in better understanding tuberculosis transmission. However, it will most efficiently contribute to tuberculosis control when implemented in an integrated public health system.
Collapse
Affiliation(s)
- C Allix-Béguec
- Laboratoire Tuberculose et Mycobactéries, Institut Pasteur, Bruxelles (Institut Scientifique de Santé Publique), rue Engeland 642, 1180 Bruxelles, Belgium
| | | | | | | | | |
Collapse
|
6
|
Johnson S, Brusasca P, Lyashchenko K, Spencer JS, Wiker HG, Bifani P, Shashkina E, Kreiswirth B, Harboe M, Schluger N, Gomez M, Gennaro ML. Characterization of the secreted MPT53 antigen of Mycobacterium tuberculosis. Infect Immun 2001; 69:5936-9. [PMID: 11500477 PMCID: PMC98717 DOI: 10.1128/iai.69.9.5936-5939.2001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
MPT53 is a secreted protein of Mycobacterium tuberculosis. Southern transfer and hybridization showed mpt53 to be conserved in the M. tuberculosis complex and to have homology with DNA from Mycobacterium avium and other nontuberculous mycobacteria. However, anti-MPT53 polyclonal antibodies detected no antigen in the culture filtrates of M. avium and other nontuberculous mycobacteria. MPT53 of M. tuberculosis induced strong, tuberculosis-specific antibody responses in guinea pigs but induced no delayed-type hypersensitivity. Involvement in immune responses during human tuberculosis was very modest.
Collapse
Affiliation(s)
- S Johnson
- Public Health Research Institute, New York, New York 10016, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Bifani P, Mathema B, Campo M, Moghazeh S, Nivin B, Shashkina E, Driscoll J, Munsiff SS, Frothingham R, Kreiswirth BN. Molecular identification of streptomycin monoresistant Mycobacterium tuberculosis related to multidrug-resistant W strain. Emerg Infect Dis 2001; 7:842-8. [PMID: 11747697 PMCID: PMC2631879 DOI: 10.3201/eid0705.010512] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
A distinct branch of the Mycobacterium tuberculosis W phylogenetic lineage (W14 group) has been identified and characterized by various genotyping techniques. The W14 group comprises three strain variants: W14, W23, and W26, which accounted for 26 clinical isolates from the New York City metropolitan area. The W14 group shares a unique IS6110 hybridizing banding motif as well as distinct polymorphic GC-rich repetitive sequence and variable number tandem repeat patterns. All W14 group members have high levels of streptomycin resistance. When the streptomycin resistance rpsL target gene was sequenced, all members of this strain family had an identical mutation in codon 43. Patients infected with the W14 group were primarily of non- Hispanic black origin (77%); all were US-born. Including HIV positivity, 84% of the patients had at least one known risk factor for tuberculosis.
Collapse
Affiliation(s)
- P Bifani
- Public Health Institute Tuberculosis Center, New York, NY 10016, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Bifani P, Moghazeh S, Shopsin B, Driscoll J, Ravikovitch A, Kreiswirth BN. Molecular characterization of Mycobacterium tuberculosis H37Rv/Ra variants: distinguishing the mycobacterial laboratory strain. J Clin Microbiol 2000; 38:3200-4. [PMID: 10970357 PMCID: PMC87354 DOI: 10.1128/jcm.38.9.3200-3204.2000] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The Mycobacterium tuberculosis strains H37Rv and H37Ra are the most commonly used controls for M. tuberculosis identification in the clinical and research laboratory setting. To reduce the likelihood of misidentification and possible cross-contamination with this laboratory neotype, it is important to be able to distinguish H37 from clinical isolates. To provide a reference for identifying H37, we used multiple molecular techniques to characterize H37 strains, including 18 of the most frequently used variants available through the American Type Culture Collection. Isolates were genotyped using gene probes to IS6110 and IS1085. In addition, we performed polymorphic GC-rich sequence typing (PGRS), spoligotyping, determination of variable number of tandem repeats (VNTR), and PCR amplification of the mtp40, msx4, and mpp8 polymorphic regions. Southern hybridization with IS6110 provided the most discrimination, differentiating the 18 H37 isolates into 10 discrete patterns made up of 9 H37Rv variants and 1 H37Ra variant. PGRS, IS1085, mpp8, and spoligotyping were not able to distinguish any H37 variants, while VNTR and msx4 discriminated two. Only IS6110 and spoligotyping could distinguish the H37 strain from clinical isolates. In summary, spoligotyping and IS6110 provide a rapid and accurate way to identify H37 contamination, though IS6110 can, in addition, classify many of the H37 variants that would otherwise require phenotypic segregation.
Collapse
Affiliation(s)
- P Bifani
- Public Health Research Institute Tuberculosis Center, New York University School of Medicine, New York, New York 10016, USA
| | | | | | | | | | | |
Collapse
|
9
|
Abstract
Spoligotype analysis identified false-positive isolates of Mycobacterium tuberculosis caused by laboratory cross-contamination. Spoligotyping is faster, is less expensive than DNA fingerprinting, and can be used with a variety of media. Patients were reevaluated and had medications discontinued as a result of this investigation. Months of unnecessary patient follow-up and treatment were avoided.
Collapse
Affiliation(s)
- B Nivin
- New York City Department of Health, Tuberculosis Control Program, New York 10007, USA
| | | | | | | | | |
Collapse
|
10
|
Colangeli R, Spencer JS, Bifani P, Williams A, Lyashchenko K, Keen MA, Hill PJ, Belisle J, Gennaro ML. MTSA-10, the product of the Rv3874 gene of Mycobacterium tuberculosis, elicits tuberculosis-specific, delayed-type hypersensitivity in guinea pigs. Infect Immun 2000; 68:990-3. [PMID: 10639479 PMCID: PMC97238 DOI: 10.1128/iai.68.2.990-993.2000] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
In a search for new skin test reagents specific for tuberculosis, we found that the antigen encoded by gene Rv3874 of Mycobacterium tuberculosis elicited delayed-type hypersensitivity in M. tuberculosis-infected guinea pigs but not in control animals immunized with Mycobacterium bovis bacillus Calmette-Guérin (BCG) or Mycobacterium avium. The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.
Collapse
Affiliation(s)
- R Colangeli
- Public Health Research Institute, New York, New York 10016, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Sreevatsan S, Escalante P, Pan X, Gillies DA, Siddiqui S, Khalaf CN, Kreiswirth BN, Bifani P, Adams LG, Ficht T, Perumaalla VS, Cave MD, van Embden JD, Musser JM. Identification of a polymorphic nucleotide in oxyR specific for Mycobacterium bovis. J Clin Microbiol 1996; 34:2007-10. [PMID: 8818900 PMCID: PMC229172 DOI: 10.1128/jcm.34.8.2007-2010.1996] [Citation(s) in RCA: 93] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Automated sequence analysis of a 410-bp region of the axyR gene in 105 Mycobacterium tuberculosis complex isolates identified a polymorphic nucleotide that differentiated Mycobacterium bovis isolates from other complex members. All 29 M. bovis isolates sequenced had an adenine residue at nucleotide 285, whereas all 76 other complex isolates had a guanine residue. PCR-restriction fragment length polymorphism analysis of oxyR with restriction endonuclease AluI in an additional 255 complex isolates from widespread intercontinental sources confirmed and extended the unique association of adenine at position 285 with M. bovis isolates.
Collapse
Affiliation(s)
- S Sreevatsan
- Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|